Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis

Ageing Research Reviews

Volumn 40, Issue , 2017, Pages 31-44

  Campbell, Jared M ^a,b   Bellman, Susan M ^a   Stephenson, Matthew D ^a   Lisy , Karolina ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

ageing; Geroprotection; Insulin sensitizer; Lifespan; Longevity; Metformin

Indexed keywords

METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; INSULIN;

AGING; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DISEASE CONTROL; EMBASE; HEART FAILURE; HEART INFARCTION; HUMAN; LONGEVITY; MALIGNANT NEOPLASM; MEDLINE; META ANALYSIS; MORTALITY; MORTALITY RISK; REVIEW; SYSTEMATIC REVIEW; CASE CONTROL STUDY; DRUG EFFECT; METABOLISM; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; TREATMENT OUTCOME;

AGING; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; NEOPLASMS; OBSERVATIONAL STUDIES AS TOPIC; TREATMENT OUTCOME;

EID: 85027587777     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2017.08.003     Document Type: Review

References (95)

1. Algire, C., Moiseeva, O., Deschenes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., Pollak, M.N., Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev. Res. (Phila.) 5 (2012), 536–543.
2. Andersson, C., Vaag, A., Selmer, C., Schmiegelow, M., Sørensen, R., Lindhardsen, J., Gislason, G.H., Køber, L., Torp-Pedersen, C., Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open, 2, 2012.
3. Andreadis, E.A., Katsanou, P.M., Georgiopoulos, D.X., Tsourous, G.I., Yfanti, G.K., Gouveri, E.T., Diamantopoulos, E.J., The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects–the Carmos study. Exp. Clin. Endocrinol. Diabetes 117 (2009), 175–180.
4. Anisimov, V.N., Egormin, P.A., Piskunova, T.S., Popovich, I.G., Tyndyk, M.L., Yurova, M.N., Zabezhinski, M.A., Anikin, I.V., Karkach, A.S., Romanyukha, A.A., Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. ABBV Cell Cycle 9 (2010), 188–197.
5. Anisimov, V.N., Piskunova, T.S., Popovich, I.G., Zabezhinski, M.A., Tyndyk, M.L., Egormin, P.A., Yurova, M.V., Rosenfeld, S.V., Semenchenko, A.V., Kovalenko, I.G., Poroshina, T.E., Berstein, L.M., Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY) 2 (2010), 945–958.
6. Anisimov, V.N., Berstein, L.M., Popovich, I.G., Zabezhinski, M.A., Egormin, P.A., Piskunova, T.S., Semenchenko, A.V., Tyndyk, M.L., Yurova, M.N., Kovalenko, I.G., Poroshina, T.E., If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 3 (2011), 148–157.
7. Azoulay, L., Dell'Aniello, S., Gagnon, B., Pollak, M., Suissa, S., Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomarkers Prev. 20 (2011), 337–344.
8. Bannister, C.A., Holden, S.E., Jenkins-Jones, S., Morgan, C.L., Halcox, J.P., Schernthaner, G., Mukherjee, J., Currie, C.J., Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes. Metab. 16 (2014), 1165–1173.
9. Barzilai, N., Crandall, J.P., Kritchevsky, S.B., Espeland, M.A., Metformin as a tool to target aging. Cell Metab. 23 (2016), 1060–1065.
10. Batandier, C., Guigas, B., Detaille, D., El-Mir, M.Y., Fontaine, E., Rigoulet, M., Leverve, X.M., The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J. Bioenerg. Biomembr. 38 (2006), 33–42.
11. Baur, D.M., Klotsche, J., Hamnvik, O.P., Sievers, C., Pieper, L., Wittchen, H.U., Stalla, G.K., Schmid, R.M., Kales, S.N., Mantzoros, C.S., Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60 (2011), 1363–1371.
12. Becker, C., Meier, C.R., Jick, S.S., Bodmer, M., Case-control analysis on metformin and cancer of the esophagus. Cancer Causes Control 24 (2013), 1763–1770.
13. Becker, C., Jick, S.S., Meier, C.R., Bodmer, M., Metformin and the risk of head and neck cancer: a case-control analysis. Diabetes Obes. Metab. 16 (2014), 1148–1154.
14. Becker, C., Jick, S.S., Meier, C.R., Bodmer, M., Metformin and the risk of renal cell carcinoma: a case-control analysis. Eur. J. Cancer Prev. 26:3 (2016), 257–262.
15. Berard, E., Bongard, V., Arveiler, D., Dallongeville, J., Wagner, A., Montaye, M., Ruidavets, J.B., Ferrieres, J., 14-year risk of all-cause mortality according to hypoglycemic drug exposure in a general population. Eur. Heart J. 32 (2011), 973–974.
16. Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E., Grassi, G., Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes. Metab. 14 (2012), 23–29.
17. Bodmer, M., Meier, C., Krahenbuhl, S., Jick, S.S., Meier, C.R., Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33 (2010), 1304–1308.
18. Bodmer, M., Becker, C., Jick, S.S., Meier, C.R., Metformin does not alter the risk of lung cancer: a case-control analysis. Lung Cancer 78 (2012), 133–137.
19. Bodmer, M., Becker, C., Meier, C., Jick, S.S., Meier, C.R., Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am. J. Gastroenterol. 107 (2012), 620–626.
20. Bosco, J.L.F., Antonsen, S., Sorensen, H.T., Pedersen, L., Lash, T.L., Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol. Biomark. Prev. 20 (2011), 101–111.
21. But, A., Wang, H., Mannisto, S., Pukkala, E., Haukka, J., Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk. PLoS One, 9, 2014, e113162.
22. Cabreiro, F., Au, C., Leung, K.Y., Vergara-Irigaray, N., Cocheme, H.M., Noori, T., Weinkove, D., Schuster, E., Greene, N.D., Gems, D., Metformin retards aging in C elegans by altering microbial folate and methionine metabolism. Cell 153 (2013), 228–239.
23. Campbell, J.M., Stephenson, M.D., de Courten, B., Chapmean, I., Bellman, S.M., Aromataris, E., Metformin and Alzheimer's disease, dementia and cognitive impairment: a systematic review protocol. JBI Database Syst. Rev. Implement Rep. 117:2 (2017), 210–219.
24. Chen, H.P., Shieh, J.J., Chang, C.C., Chen, T.T., Lin, J.T., Wu, M.S., Lin, J.H., Wu, C.Y., Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62 (2013), 606–615.
25. Claesen, M., Gillard, P., De Smet, F., Callens, M., De Moor, B., Mathieu, C., Mortality in individuals treated with glucose-lowering agents: a large, controlled cohort study. J. Clin. Endocrinol. Metab. 101 (2016), 461–469.
26. Coyle, C., Cafferty, F.H., Vale, C., Langley, R.E., Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 27 (2016), 2184–2195.
27. Ekstrom, N., Schioler, L., Svensson, A.M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., Gudbjornsdottir, S., Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open, 2012, 2.
28. Evans, J.M., Ogston, S.A., Emslie-Smith, A., Morris, A.D., Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (2006), 930–936.
29. Finkel, T., Holbrook, N.J., Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000), 239–247.
30. Floyd, J.S., Wiggins, K.L., Christiansen, M., Dublin, S., Longstreth, W.T., Smith, N.L., McKnight, B., Heckbert, S.R., Weiss, N.S., Psaty, B.M., Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. Pharmacoepidemiol. Drug Saf. 25 (2016), 151–160.
31. Garinis, G.A., van der Horst, G.T., Vijg, J., Hoeijmakers, J.H., DNA damage and ageing: new-age ideas for an age-old problem. Nat. Cell Biol. 10 (2008), 1241–1247.
32. Gash, K.J., Chambers, A.C., Cotton, D.E., Williams, A.C., Thomas, M.G., Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. Br. J. Cancer 117:2 (2017), 210–219.
33. Gejl, M., Starup-Linde, J., Scheel-Thomsen, J., Gregersen, S., Vestergaard, P., Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs – a nested case-control study. Int. J. Cardiol. 178 (2015), 292–296.
34. Geoghegan, J.M., Clark, D.I., Bainbridge, L.C., Smith, C., Hubbard, R., Risk factors in carpal tunnel syndrome. J. Hand Surg. Br. 29 (2004), 315–320.
35. Ghotbi, A.A., Kober, L., Finer, N., James, W.P., Sharma, A.M., Caterson, I., Coutinho, W., Van Gaal, L.F., Torp-Pedersen, C., Andersson, C., Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care 36 (2013), 3746–3753.
36. Gillespie, Z.E., Pickering, J., Eskiw, C.H., Better living through chemistry: caloric restriction (CR) and CR mimetics alter genome function to promote increased health and lifespan. Front. Genet., 7, 2016, 142.
37. Giorda, C.B., Cioffi, G., De Simone, G., Di Lenarda, A., Faggiano, P., Latini, R., Lucci, D., Maggioni, A.P., Tarantini, L., Velussi, M., Verdecchia, P., Comaschi, M., Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur. J. Cardiovasc. Prev. Rehabil. 18 (2011), 415–423.
38. Goossens, M.E., Buntinx, F., Zeegers, M.P., Driessen, J.H., De Bruin, M.L., De Vries, F., Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. Br. J. Clin. Pharmacol. 80 (2015), 1464–1472.
39. Gosmanova, E.O., Canada, R.B., Mangold, T.A., Rawls, W.N., Wall, B.M., Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am. J. Med. Sci. 336 (2008), 241–247.
40. Hartung, D.M., Touchette, D.R., Bultemeier, N.C., Haxby, D.G., Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy 25 (2005), 1329–1336.
41. Hung, A.M., Roumie, C.L., Greevy, R.A., Liu, X., Grijalva, C.G., Murff, H.J., Griffin, M.R., Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol. Drug Saf. 22 (2013), 623–631.
42. Jansson, S.P., Svardsudd, K., Andersson, D.K., Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up. Diabet. Med. 31 (2014), 1055–1063.
43. Kahler, K.H., Rajan, M., Rhoads, G.G., Safford, M.M., Demissie, K., Lu, S.E., Pogach, L.M., Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 30 (2007), 1689–1693.
44. Kahn, S.E., Zinman, B., Lachin, J.M., Haffner, S.M., Herman, W.H., Holman, R.R., Kravitz, B.G., Yu, D., Heise, M.A., Aftring, R.P., Viberti, G., Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31 (2008), 845–851.
45. Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Kohler, A., Glossmann, H., Schneider, R., Sutherland, C., Schweiger, S., Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 21830–21835.
46. Knowler, W.C., Fowler, S.E., Hamman, R.F., Christophi, C.A., Hoffman, H.J., Brenneman, A.T., Brown-Friday, J.O., Goldberg, R., Venditti, E., Nathan, D.M., 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374 (2009), 1677–1686.
47. Kooy, A., De Jager, J., Lehert, P., Bets, D., Wulffelé, M.G., Donker, A.J.M., Stehouwer, C.D.A., Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169 (2009), 616–625.
48. Koro, C.E., Bowlin, S.J., Weiss, S.R., Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol. Drug Saf. 14 (2005), 697–703.
49. Lee, S.H., Min, K.J., Caloric restriction and its mimetics. BMB Rep. 46 (2013), 181–187.
50. Li, Y., Hu, L., Xia, Q., Yuan, Y., Mi, Y., The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. Int. Urol. Nephrol. 49 (2017), 975–981.
51. Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., Evans, J.M., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 (2009), 1620–1625.
52. Lin, H.C., Stein, J.D., Nan, B., Childers, D., Newman-Casey, P.A., Thompson, D.A., Richards, J.E., Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. 133 (2015), 915–923.
53. Liu, B., Fan, Z., Edgerton, S.M., Yang, X., Lind, S.E., Thor, A.D., Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. ABBV Cell Cycle 10 (2011), 2959–2966.
54. Liu, F., Yan, L., Wang, Z., Lu, Y., Chu, Y., Li, X., Liu, Y., Rui, D., Nie, S., Xiang, H., Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget 8 (2017), 16017–16026.
55. Lu, Y., Garcia Rodriguez, L.A., Malgerud, L., Gonzalez-Perez, A., Martin-Perez, M., Lagergren, J., Bexelius, T.S., New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br. J. Cancer 113 (2015), 1607–1614.
56. Ma, S., Zheng, Y., Xiao, Y., Zhou, P., Tan, H., Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore), 96, 2017, e6888.
57. Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., Palacios, H.H., Mote, P.L., Scheibye-Knudsen, M., Gomes, A.P., Ward, T.M., Minor, R.K., Blouin, M.J., Schwab, M., Pollak, M., Zhang, Y., Yu, Y., Becker, K.G., Bohr, V.A., Ingram, D.K., Sinclair, D.A., Wolf, N.S., Spindler, S.R., Bernier, M., de Cabo, R., Metformin improves healthspan and lifespan in mice. Nat. Commun., 4, 2013, 2192.
58. Masica, A.L., Ewen, E., Daoud, Y.A., Cheng, D., Franceschini, N., Kudyakov, R.E., Bowen, J.R., Brouwer, E.S., Wallace, D., Fleming, N.S., West, S.L., Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease. Pharmacoepidemiol. Drug Saf. 22 (2013), 413–422.
59. Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3, 2006, e442.
60. Mazzone, P.J., Rai, H., Beukemann, M., Xu, M., Jain, A., Sasidhar, M., The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer, 12, 2012.
61. McAlister, F.A., Eurich, D.T., Majumdar, S.R., Johnson, J.A., The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur. J. Heart Fail. 10 (2008), 703–708.
62. Meng, F., Song, L., Wang, W., Metformin improves overall survival of colorectal cancer patients with diabetes: a meta-analysis. J Diabetes Res., 2017, 2017, 5063239.
63. Mitchell, G.F., Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J. Appl. Physiol. (1985) 105 (2008), 1652–1660.
64. Na, H.J., Park, J.S., Pyo, J.H., Lee, S.H., Jeon, H.J., Kim, Y.S., Yoo, M.A., Mechanism of metformin: inhibition of DNA damage and proliferative activity in Drosophila midgut stem cell. Mech. Ageing Dev. 134 (2013), 381–390.
65. Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues Hoffman, A., Safe, S., Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J. Biol. Chem. 289 (2014), 27692–27701.
66. Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., Zinman, B., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006), 1963–1972.
67. Ng, T.P., Feng, L., Yap, K.B., Lee, T.S., Tan, C.H., Winblad, B., Long-term metformin usage and cognitive function among older adults with diabetes. J. Alzheimers Dis. 41 (2014), 61–68.
68. Nichols, G.A., Koro, C.E., Gullion, C.M., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab. Res. Rev. 21 (2005), 51–57.
69. Nordström, T., Clements, M., Karlsson, R., Adolfsson, J., Grönberg, H., The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur. J. Cancer 51 (2015), 725–733.
70. Peters, K.E., Chubb, S.A., Davis, W.A., Davis, T.M., The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study. PLoS One, 8, 2013, e74355.
71. Pladevall, M., Riera-Guardia, N., Margulis, A.V., Varas-Lorenzo, C., Calingaert, B., Perez-Gutthann, S., Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovasc. Disord., 16, 2016, 14.
72. Pratipanawatr, T., Rawdaree, P., Chetthakul, T., Bunnag, P., Ngarmukos, C., Benjasuratwong, Y., Leelawatana, R., Kosachunhanun, N., Plengvidhya, N., Deerochanawong, C., Suwanwalaikorn, S., Krittiyawong, S., Mongkolsomlit, S., Komoltri, C., Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. J. Med. Assoc. Thai. 93:Suppl. (3) (2010), S12–S20.
73. Redaniel, M.T., Jeffreys, M., May, M.T., Ben-Shlomo, Y., Martin, R.M., Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 23 (2012), 1785–1795.
74. Rojas, L.B., Gomes, M.B., Metformin: an old but still the best treatment for type 2 diabetes. Diabetol. Metab. Syndr., 5, 2013, 6.
75. Roth, G.S., Ingram, D.K., Manipulation of health span and function by dietary caloric restriction mimetics. Ann. N. Y. Acad. Sci. 1363 (2016), 5–10.
76. Saisho, Y., Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr. Metab. Immune Disord. Drug Targets 15 (2015), 196–205.
77. Sehdev, A., Shih, Y.C.T., Vekhter, B., Bissonnette, M.B., Olopade, O.I., Polite, B.N., Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer 121 (2015), 1071–1078.
78. Smiechowski, B., Azoulay, L., Yin, H., Pollak, M.N., Suissa, S., The use of metformin and colorectal cancer incidence in patients with type ii diabetes mellitus. Cancer Epidemiol. Biomark. Prev. 22 (2013), 1877–1883.
79. Smiechowski, B.B., Azoulay, L., Yin, H., Pollak, M.N., Suissa, S., The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36 (2013), 124–129.
80. Sullivan, D., Forder, P., Simes, J., Whiting, M., Kritharides, L., Merrifield, A., Donoghoe, M., Colman, P.G., Graham, N., Haapamaki, H., Keech, A., Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res. Clin. Pract. 94 (2011), 284–290.
81. Tang, Y.L., Zhu, L.Y., Li, Y., Yu, J., Wang, J., Zeng, X.X., Hu, K.X., Liu, J.Y., Xu, J.X., Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis. BioMed Res. Int., 2017, 2017.
82. The Joanna Briggs Institute, 2014. The Joanna Briggs Institute Reviewer's Manual: 2014 edition, Australia.
83. Tierney, J.F., Stewart, L.A., Ghersi, D., Burdett, S., Sydes, M.R., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16.
84. Tseng, C.H., Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54 (2011), 2009–2015.
85. Tseng, C.H., Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur. J. Endocrinol. 167 (2012), 409–416.
86. Tseng, C.H., Thyroid cancer risk is not increased in diabetic patients. PLoS One, 7, 2012.
87. Vasisht, K.P., Chen, S.C., Peng, Y., Bakris, G.L., Limitations of metformin use in patients with kidney disease: are they warranted?. Diabetes Obes. Metab. 12 (2010), 1079–1083.
88. Vestergaard, P., Rejnmark, L., Mosekilde, L., Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48 (2005), 1292–1299.
89. Walker, E.J., Ko, A.H., Holly, E.A., Bracci, P.M., Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int. J. Cancer 136 (2015), E646–E653.
90. Wang, C.P., Lorenzo, C., Espinoza, S.E., Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. J. Endocrinol. Diabetes Obes., 2, 2014.
91. Wang, C.P., Lorenzo, C., Habib, S.L., Jo, B., Espinoza, S.E., Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. J. Diabetes Complications 31 (2017), 679–686.
92. Zheng, Z., Chen, H., Li, J., Li, T., Zheng, B., Zheng, Y., Jin, H., He, Y., Gu, Q., Xu, X., Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 61 (2012), 217–228.
93. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001), 1167–1174.
94. Zhou, P.T., Li, B., Liu, F.R., Zhang, M.C., Wang, Q., Li, Y.Y., Xu, C., Liu, Y.H., Yao, Y., Li, D., Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 8 (2017), 25242–25250.
95. Zhou, X.L., Xue, W.H., Ding, X.F., Li, L.F., Dou, M.M., Zhang, W.J., Lv, Z., Fan, Z.R., Zhao, J., Wang, L.X., Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies. Oncotarget, 2017.